Canagliflozin as an initial therapy in drug-naïve subjects with type 2 diabetes mellitus: A potential involvement of atherogenic lipids in its glycemic efficacy - Kutoh, E; Wada, A; Murayama, T (Drugs R D, 2017)
et al.